Delivery Order 36F79721D0166-75A50324F80012
Award Date
9/30/24
Potential Completion Date
9/29/29
Potential Value
$69M
Awardee
Biocryst Pharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Durham, NC 27703, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a Definitive Contract to Biocryst Pharmaceuticals Inc., a for-profit biotechnology company, for the delivery of PERAMIVIR, RAPIVAB flu treatment. The contract has a Firm Fixed Price pricing type, a potential value of $34,660,000.00, and a period of performance through August 31, 2023. This contract is not associated with a set-aside designation. Biocryst Pharmaceuticals is a...
This federal contract award is for a delivery order under Biocryst Pharmaceuticals Inc.'s Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) with the U.S. Department of Veterans Affairs (VA). The award, valued at $387,618.82, is for the bulk ordering of ORLADEYO, a medication used to treat hereditary angioedema. The contract has an ultimate completion date of March 11, 2025. Biocryst Pharmaceuticals is a biotechnology company that specializes in developing small...
This federal contract award is for ORLADEYO EMERGENT, a pharmaceutical product, to Biocryst Pharmaceuticals Inc. as the prime contractor. The contract has a ceiling value of $29,649.88 and is a delivery order under Biocryst's Federal Supply Schedule (FSS) contract (36F79721D0166) for Pharmaceuticals and Drugs with the Department of Veterans Affairs (VA). Biocryst is a biotechnology company that specializes in the development of small molecule drugs for rare diseases, and it primarily supplies...
This is a delivery order contract awarded to Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing small molecule drugs for rare diseases. The contract is valued at $201,721.59 and has an ultimate completion date of October 4, 2024. The contract is for the delivery of ORLADEYO 150MG CAPS, a pharmaceutical product used to treat hereditary angioedema. The contract was awarded by the U.S. Department of Veterans Affairs (VA), specifically the Veterans Integrated...
This federal contract award, valued at $1,238.40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution company. The contract is for the delivery of Oseltamivir Phosphate 75 mg capsules. The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., which is valued at up to $999,999,999.00 and runs through December 2025. This single-award IDC serves as the primary vehicle...
This federal contract award, valued at $1,459.36, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4567197543 ! OSELTAMIVIR 6 MG/ML SUSPENSION 60ML, a medication used for the treatment of influenza. The contract has a period of performance through February 10, 2025 and is a firm fixed-price delivery order. This award is part of a larger Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,130.01 firm fixed-price delivery order is for the supply of 60 ml bottles of the antiviral medication Oseltamivir, with a performance period ending on February 13, 2025. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite...
This federal contract award is a delivery order valued at $1,494.60 placed by the Defense Logistics Agency (DLA) with AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award is for the supply of 4,563,471,961 units of the drug Oseltamivir Phosphate 75 mg capsules, an antiviral medication used to treat and prevent influenza. The contract has an ultimate completion date of January 30, 2024 and was awarded on January 29, 2024. It is a firm fixed-price contract with no set-aside...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,090.00, is a delivery order for the procurement of 75 mg Oseltamivir Phosphate capsules. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for providing a...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,981.18 firm fixed-price delivery order is for the supply of HYPERRAB 300UNIT/ML 1S, a pharmaceutical product. The contract has an ultimate completion date of February 29, 2024. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...